Vistagen Therapeutics, Inc. (VTGN) income statement
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.20+0.01 (+6.12%)
Close on Nov 18, 2026Market cap $8.85MP/E –Yield –
Vistagen Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -2784.3%
- Net margin
- -2702.6%
- Return on equity, FY2026
- -131.6%
Financial strength
- Current ratio
- 3.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 151.8%
Valuation
- P/E ratio
- –
- Price to sales
- 3.54
- Price to book
- 0.36
- Dividend yield
- –
See a number that looks wrong?